Baicalein Inhibits Formation of α‐Synuclein Oligomers within Living Cells and Prevents Aβ Peptide Fibrillation and Oligomerisation
暂无分享,去创建一个
Jian-Dong Huang | Min Li | Jia-Hong Lu | O. El‐Agnaf | Jian-Dong Huang | W. Fong | Li-Xia Xie | Siva Sundara Kumar Durairajan | Omar M A El-Agnaf | Liang-Feng Liu | Jiahong Lu | Min Li | L. Xie | S. Durairajan | M. Hasan | M. Ardah | Mustafa Taleb Ardah | Wang-Fun David Fong | Mohamed Y Hasan | O. El-Agnaf | Liang-feng Liu
[1] G. Du,et al. Neuroprotective effect of baicalein against MPTP neurotoxicity: Behavioral, biochemical and immunohistochemical profile , 2008, Neuroscience Letters.
[2] V. Uversky,et al. Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. , 2008, Journal of molecular biology.
[3] C. Ross,et al. Single Particle Characterization of Iron-induced Pore-forming α-Synuclein Oligomers* , 2008, Journal of Biological Chemistry.
[4] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[5] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[6] K. Ono,et al. Ferulic acid destabilizes preformed β-amyloid fibrils in vitro , 2005 .
[7] A. Shum,et al. The effects of the cyclosporin A, a P‐glycoprotein inhibitor, on the pharmacokinetics of baicalein in the rat: a microdialysis study , 2002, British journal of pharmacology.
[8] D. Ehrnhoefer,et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers , 2008, Nature Structural &Molecular Biology.
[9] P. Fraser,et al. Manipulating the Amyloid-β Aggregation Pathway with Chemical Chaperones* , 1999, The Journal of Biological Chemistry.
[10] R. Kayed,et al. Permeabilization of Lipid Bilayers Is a Common Conformation-dependent Activity of Soluble Amyloid Oligomers in Protein Misfolding Diseases* , 2004, Journal of Biological Chemistry.
[11] H. Milani,et al. Sustained neuroprotection and facilitation of behavioral recovery by the Ginkgo biloba extract, EGb 761, after transient forebrain ischemia in rats , 2006, Behavioural Brain Research.
[12] Fang Wang,et al. Baicalein improves cognitive deficits induced by chronic cerebral hypoperfusion in rats , 2007, Pharmacology Biochemistry and Behavior.
[13] Z. Bian,et al. Efficacy and safety of herbal medicines for idiopathic Parkinson's disease: A systematic review , 2006, Movement disorders : official journal of the Movement Disorder Society.
[14] E. Israeli,et al. β‐Synuclein occurs in vivo in lipid‐associated oligomers and forms hetero‐oligomers with α‐synuclein , 2009, Journal of neurochemistry.
[15] Bradley T. Hyman,et al. Formation of Toxic Oligomeric α-Synuclein Species in Living Cells , 2008, PloS one.
[16] E. Bigio,et al. Monoclonal antibodies that target pathological assemblies of Aβ , 2007, Journal of neurochemistry.
[17] W. Klein,et al. Salvianolic acid B inhibits Aβ fibril formation and disaggregates preformed fibrils and protects against Aβ-induced cytotoxicty , 2008, Neurochemistry International.
[18] K. Fischbeck,et al. Toxic Proteins in Neurodegenerative Disease , 2002, Science.
[19] Fusheng Yang,et al. Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.
[20] G. Du,et al. Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro , 2009, Pharmacology Biochemistry and Behavior.
[21] P. Lansbury,et al. Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α-Synuclein* , 2008, Journal of Biological Chemistry.
[22] Jerzy Jankun,et al. In vivo and in vitro effect of baicalein on human prostate cancer cells. , 2005, International journal of oncology.
[23] L. Breydo,et al. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. , 2007, Biochemistry.
[24] Shubo Han,et al. The Flavonoid Baicalein Inhibits Fibrillation of α-Synuclein and Disaggregates Existing Fibrils* , 2004, Journal of Biological Chemistry.
[25] P. Butko,et al. Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[26] V. Uversky,et al. Molecular mechanisms underlying the flavonoid-induced inhibition of alpha-synuclein fibrillation. , 2009, Biochemistry.
[27] Peter T. Lansbury,et al. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.
[28] C. Chi,et al. Effects of baicalein on -amyloid peptide-(2535)-induced amnesia in mice , 2004 .
[29] M. Guo,et al. Iron-binding and anti-Fenton properties of baicalein and baicalin. , 2009, Journal of inorganic biochemistry.
[30] Akihiko Takashima,et al. Uncaria rhynchophylla, a Chinese medicinal herb, has potent antiaggregation effects on Alzheimer's β‐amyloid proteins , 2006, Journal of neuroscience research.
[31] Y. Chan,et al. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. , 2007, CNS and Neurological Disorders - Drug Targets.
[32] Li Taiming,et al. Investigation of the absorption mechanisms of baicalin and baicalein in rats. , 2006, Journal of pharmaceutical sciences.
[33] Mark R Cookson,et al. The biochemistry of Parkinson's disease. , 2005, Annual review of biochemistry.
[34] P. Lansbury,et al. Amyloid diseases: abnormal protein aggregation in neurodegeneration. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[35] D. Allsop,et al. Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] R. Kayed,et al. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis , 2006, Neurology.
[37] K. Sakurai,et al. Protection by baicalein against ascorbic acid-induced lipid peroxidation of rat liver microsomes. , 1995, Research communications in molecular pathology and pharmacology.
[38] H. Levine. Quantification of beta-sheet amyloid fibril structures with thioflavin T. , 1999, Methods in enzymology.
[39] K. Arai,et al. Baicalein and 12/15-Lipoxygenase in the Ischemic Brain , 2006, Stroke.
[40] Chao Liu,et al. Neuroprotection by baicalein in ischemic brain injury involves PTEN/AKT pathway , 2010, Journal of neurochemistry.
[41] Vladimir N. Uversky,et al. Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation , 2007 .
[42] S. Mandel,et al. Neuroprotective molecular mechanisms of (−)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties , 2009, Genes & Nutrition.
[43] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[44] C. Dobson,et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases , 2002, Nature.
[45] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[46] Yu-bin Deng,et al. Salvianolic acid B promotes survival of transplanted mesenchymal stem cells in spinal cord-injured rats , 2008, Acta Pharmacologica Sinica.
[47] Peter T. Lansbury,et al. Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.
[48] W. Klein,et al. Selective neuronal degeneration induced by soluble oligomeric amyloid beta‐protein , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[49] Hong-yu Zhang,et al. Potential Anti-Dementia Agents in Traditional Chinese Medicine , 2009, Natural product communications.
[50] Z. Cao,et al. Protective effects of baicalin on ligature-induced periodontitis in rats. , 2007, Journal of periodontal research.
[51] R. Jakes,et al. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α‐synuclein protein implicated in Parkinson's disease , 1998, FEBS letters.
[52] D. Butterfield,et al. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. , 2000, Journal of structural biology.
[53] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[54] C. Masters,et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[55] B. Hyman,et al. CHIP Targets Toxic α-Synuclein Oligomers for Degradation* , 2008, Journal of Biological Chemistry.
[56] P. Lansbury,et al. Amyloid fibrillogenesis: themes and variations. , 2000, Current opinion in structural biology.
[57] P. Lansbury,et al. Genetics of Parkinson's disease and biochemical studies of implicated gene products. , 2002, Current opinion in genetics & development.